TY - JOUR
T1 - Prostate cancer detection rates in different biopsy schemes. Which cores for which patients?
AU - Cormio, Luigi
AU - Scattoni, Vincenzo
AU - Lorusso, Fabrizio
AU - Perrone, Antonia
AU - Di Fino, Giuseppe
AU - Selvaggio, Oscar
AU - Sanguedolce, Francesca
AU - Bufo, Pantaleo
AU - Montorsi, Francesco
AU - Carrieri, Giuseppe
PY - 2014
Y1 - 2014
N2 - Purpose: To determine whether the addition of four paramedian peripheral and four lateral peripheral cores improves the cancer detection rate (CDR) of the extended 10-core biopsy scheme and which patients benefit most from such additional samples. Methods: One thousand and ninety-one consecutive patients scheduled for first ultrasound-guided transrectal prostate biopsy prospectively underwent a 18-core biopsy scheme, including the traditional sextant (6-core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral peripheral cores (18-core). Results: The CDR of the 6-, 10-, 14- and 18-core schemes was 33.1, 39.2, 41.6 and 41.8 %, respectively; the difference between the 10- and 6-core scheme reached significance (p <0.005), whereas that between the 18- or 14- and the 10-core scheme did not. The percentage of tumors diagnosed on the sole basis of the 14-core scheme was significantly greater in patients with low PSA (≤7.2 vs. >7.2 ng/ml: 12.1 vs. 1.8 %; p <0.0001), large prostate volume (≥50 vs.
AB - Purpose: To determine whether the addition of four paramedian peripheral and four lateral peripheral cores improves the cancer detection rate (CDR) of the extended 10-core biopsy scheme and which patients benefit most from such additional samples. Methods: One thousand and ninety-one consecutive patients scheduled for first ultrasound-guided transrectal prostate biopsy prospectively underwent a 18-core biopsy scheme, including the traditional sextant (6-core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral peripheral cores (18-core). Results: The CDR of the 6-, 10-, 14- and 18-core schemes was 33.1, 39.2, 41.6 and 41.8 %, respectively; the difference between the 10- and 6-core scheme reached significance (p <0.005), whereas that between the 18- or 14- and the 10-core scheme did not. The percentage of tumors diagnosed on the sole basis of the 14-core scheme was significantly greater in patients with low PSA (≤7.2 vs. >7.2 ng/ml: 12.1 vs. 1.8 %; p <0.0001), large prostate volume (≥50 vs.
KW - Diagnosis
KW - Prostate biopsy
KW - Prostatic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=84897029609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897029609&partnerID=8YFLogxK
U2 - 10.1007/s00345-012-0989-8
DO - 10.1007/s00345-012-0989-8
M3 - Article
C2 - 23184141
AN - SCOPUS:84897029609
VL - 32
SP - 341
EP - 346
JO - World Journal of Urology
JF - World Journal of Urology
SN - 0724-4983
IS - 2
ER -